Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis

45
Scientist with laboratory background and concept.

INGELHEIM, Germany–(BUSINESS WIRE)–The New England Journal of Medicine (NEJM) today published new data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved symptoms of generalised pustular psoriasis (GPP), a rare form of psoriasis.1 BI 655130 is a monoclonal antibody that blocks the action of the interleukin-36 receptor (IL-36R), a signalling pathway within the immune system that may play a role in many inflammatory diseases. The http://www.businesswire.com/news/home/20190306005904/en/Boehringer-Ingelheims-antibody-shows-potential-transform-treatment/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==